Evidence map›Paper›PMID 25745370›Full record

ReviewThe Yale journal of biology and medicine2015

The use of stem cells to study autism spectrum disorder.

Karthikeyan Ardhanareeswaran, Gianfilippo Coppola, Flora Vaccarino

Open access · greenAbstract readReview
In one paragraph

Review in The Yale journal of biology and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Decoding the genetic landscape of autism: A comprehensive review.World journal of clinical pediatrics · 2024
    Article
  2. Review
  3. Review
  4. iPSC modeling of rare pediatric disorders.Journal of neuroscience methods · 2020
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Karthikeyan ArdhanareeswaranChild Study Center, Yale School of Medicine, New Haven, Connecticut ; Program in Neurodevelopment and Regeneration, Yale School of Medicine, New Haven, Connecticut ; Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut.
Gianfilippo CoppolaChild Study Center, Yale School of Medicine, New Haven, Connecticut ; Program in Neurodevelopment and Regeneration, Yale School of Medicine, New Haven, Connecticut.
Flora VaccarinoChild Study Center, Yale School of Medicine, New Haven, Connecticut ; Program in Neurodevelopment and Regeneration, Yale School of Medicine, New Haven, Connecticut ; Yale Kavli Institute for Neuroscience, Yale School of Medicine, New Haven, Connecticut ; Department of Neurobiology, Yale School of Medicine, New Haven, Connecticut.
Yale University · US

Funding

Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Neurobiology of Autism With MacrocephalyR01MH109648 · NIMH · YALE UNIVERSITY · PI VACCARINO, FLORA M · 2016 to 2021
$3.3M
Gene regulatory elements and transcriptome in iPSCs and embryonic human cortexU01MH103365 · NIMH · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER, VACCARINO, FLORA M · 2014 to 2017
$2.4M
NCATS NIH HHS UL1 TR000142NIMH NIH HHS R01 MH109648NIMH NIH HHS U01 MH103365
6 · The paper itself

Abstract

Autism spectrum disorder (ASD) affects as many as 1 in 68 children and is said to be the fastest-growing serious developmental disability in the United States. There is currently no medical cure or diagnostic test for ASD. Furthermore, the U.S. Food and Drug Administration has yet to approve a single drug for the treatment of autism's core symptoms. Despite numerous genome studies and the identification of hundreds of genes that may cause or predispose children to ASD, the pathways underlying the pathogenesis of idiopathic ASD still remain elusive. Post-mortem brain samples, apart from being difficult to obtain, offer little insight into a disorder that arises through the course of development. Furthermore, ASD is a disorder of highly complex, human-specific behaviors, making it difficult to model in animals. Stem cell models of ASD can be generated by performing skin biopsies of ASD patients and then dedifferentiating these fibroblasts into human-induced pluripotent stem cells (hiPSCs). iPSCs closely resemble embryonic stem cells and retain the unique genetic signature of the ASD patient from whom they were originally derived. Differentiation of these iPSCs into neurons essentially recapitulates the ASD patient's neuronal development in a dish, allowing for a patient-specific model of ASD. Here we review our current understanding of the underlying neurobiology of ASD and how the use of stem cells can advance this understanding, possibly leading to new therapeutic avenues.

Indexed as

Models, BiologicalAnimalsAutism Spectrum DisorderHumansInduced Pluripotent Stem CellsNervous SystemStem Cell Transplantationautismautism spectrum disorderinduced pluripotent stem cellsstem cells

Identifiers

PMID25745370
PMCPMC4345539
OpenAlexW2262469017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.